Ambien CR launch takes hold

Share this article:
A controlled release version of the Sanofi-Aventis anti-insomnia drug zolpidem, Ambien CR has reached pharmacy shelves, the company said.
The new pill, launched October 7, is being introduced to doctors by a force of 3,500 sales reps, the firm noted.
Sanofi-Aventis is hoping CR receives a warm welcome, as top-selling Ambien is set to move off patent next year. Brand communications emphasize its indication for sleep maintenance, as well as sleep induction. Publicis' Saatchi & Saatchi family of agencies handles med ed, consumer and professional ads.
Ambien had U.S. third-quarter sales of 371 million euros ($437 million), up 4.8% from the same quarter last year, according to the drug maker. U.S. sales for the nine months ending in September reached 948 million euros ($1.1 billion), an increase of 8.8%.
The Ambien franchise faces competition from two other recently launched prescription sleep aids, Rozerem (ramelteon) from Takeda Pharmaceuticals North America and Sepracor's Lunesta (eszopiclone).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions